Your cart is empty.
Your cart is empty.

$699.00
this product is available by prescription only
Repatha 140 mg is a subcutaneous injection of evolocumab, a fully human monoclonal antibody that blocks PCSK9 — the protein responsible for destroying LDL receptors on the liver. By neutralizing PCSK9, Repatha allows more LDL receptors to remain active, enabling the liver to clear significantly more bad cholesterol from the bloodstream. Supplied as a single-use pre-filled autoinjector, it is designed for straightforward self-administration. Cold-chain storage at 2°C–8°C is required throughout the supply chain.
Repatha delivers one of the most powerful LDL-lowering effects available — reducing LDL-C by 55 to 75% on top of statin therapy. The FOURIER outcomes trial confirmed that this translates directly into fewer cardiovascular events: a 27% reduction in heart attack risk and a 21% reduction in stroke risk compared to placebo in patients with established cardiovascular disease. For patients with familial hypercholesterolemia or those who cannot reach LDL targets on statins alone, Repatha provides meaningful, proven protection.
For hypercholesterolemia and primary LDL-C reduction: inject 140 mg subcutaneously every two weeks, or 420 mg once monthly using three consecutive injections within 30 minutes. For homozygous familial hypercholesterolemia: 420 mg monthly, with option to increase to every two weeks if response is inadequate. Allow the autoinjector to reach room temperature for 30 minutes before use. Rotate injection sites. Repatha must be stored at 2°C–8°C and must not be frozen. A prescription is required.
This website contains information on research compounds intended for laboratory use only. You must be 21 years or older to enter and view this content. By entering, you also agree that all products are for research use only and are not intended for human consumption.
We'll send the lab results to this email address.